Skip to content

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03118232
Acronym
PROTECT
Enrollment
13952
Registered
2017-04-18
Start date
2017-04-03
Completion date
2023-10-10
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospitalization, Infection

Keywords

Nursing Homes, Health Facilities, Infections, Readmissions, Multi-Drug resistance, Antibiotic Use

Brief summary

This is a cluster-randomized trial of nursing homes to assess whether decolonization with routine chlorhexidine bathing and periodic use of nasal antiseptics can reduce hospitalizations associated with infections, antibiotic utilization, and multi-drug resistant organism (MDRO) prevalence. The comparator arm will be routine bathing care.

Interventions

2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.

DRUGIodophor (10% povidone-iodine)

Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.

Sponsors

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
CollaboratorOTHER
University of Massachusetts, Amherst
CollaboratorOTHER
Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED
University of California, Irvine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Nursing homes will be eligible to participate if they meet the following criteria: * Licensed nursing home in Orange County or Southern Los Angeles County serving adults * Minimal use of chlorhexidine bathing\* * Minimal use of nasal decolonization\* \*Minimal use defined as \<15% of residents receiving at least one chlorhexidine bath or nasal decolonization treatment during their nursing home stay.

Exclusion criteria

Nursing homes will not be eligible to participate if they meet the following criteria: * Facilities routinely using decolonization * Dedicated psychiatric nursing homes * Facilities with a resident population with \>=20% combative patients * Pediatric facilities Note: in any participating nursing home, residents with active end-of-life comfort care only measures are excluded

Design outcomes

Primary

MeasureTime frameDescription
Hospital Transfers Due to Infection18 monthsProbability that a transfer to a hospital is due to an infection

Secondary

MeasureTime frameDescription
All Hospital Transfers18 monthsProbability that a discharge is to a hospital

Other

MeasureTime frameDescription
Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)Once in baseline and once at end-intervention (month 15-18 of intervention period)Probability of colonization with any multidrug-resistant organism (MDRO): (MRSA, VRE, ESBL, CRE)
Hospital Transfers Due to Infection in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)18 monthsProbability that a transfer to a hospital is due to an infection for long stay and short stay resident subsets
All Hospital Transfers in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)18 monthsProbability that a discharge is to a hospital for long stay and short stay resident subsets
Emergency Department Transfers Due to Infection (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)18 monthsProbability that a resident is sent to the emergency department for an infection, overall for long stay and short stay resident subsets

Countries

United States

Participant flow

Participants by arm

ArmCount
Decolonization
Nursing homes assigned to this arm will perform decolonization using topical antiseptic products. Chlorhexidine gluconate (CHG): 2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing. Iodophor (10% povidone-iodine): Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
7,388
Routine Bathing
Routine bathing per facility protocol.
6,564
Total13,952

Baseline characteristics

CharacteristicDecolonizationTotalRoutine Bathing
Age, Continuous75.7 years
STANDARD_DEVIATION 4.2
76.2 years
STANDARD_DEVIATION 5
76.6 years
STANDARD_DEVIATION 5.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1042 Participants2354 Participants1312 Participants
Race (NIH/OMB)
Black or African American
841 Participants1883 Participants1042 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1756 Participants3300 Participants1544 Participants
Race (NIH/OMB)
White
3749 Participants6415 Participants2666 Participants
Region of Enrollment
United States
7388 Participants13952 Participants6564 Participants
Sex: Female, Male
Female
4180 Participants7782 Participants3602 Participants
Sex: Female, Male
Male
3208 Participants6170 Participants2962 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 7,3880 / 6,564
other
Total, other adverse events
35 / 7,3880 / 6,564
serious
Total, serious adverse events
0 / 7,3880 / 6,564

Outcome results

Primary

Hospital Transfers Due to Infection

Probability that a transfer to a hospital is due to an infection

Time frame: 18 months

Population: Analysis is of residents accounting for clustering in 28 nursing homes

ArmMeasureValue (NUMBER)
DecolonizationHospital Transfers Due to Infection1243 Transfers
Routine BathingHospital Transfers Due to Infection1780 Transfers
p-value: <0.00195% CI: [11, 21.8]Mixed Models Analysis
Secondary

All Hospital Transfers

Probability that a discharge is to a hospital

Time frame: 18 months

Population: Analysis is of residents accounting for clustering in 28 nursing homes

ArmMeasureValue (NUMBER)
DecolonizationAll Hospital Transfers2388 Transfers
Routine BathingAll Hospital Transfers2857 Transfers
p-value: <0.00195% CI: [9.7, 19.2]Mixed Models Analysis
Other Pre-specified

All Hospital Transfers in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)

Probability that a discharge is to a hospital for long stay and short stay resident subsets

Time frame: 18 months

Other Pre-specified

Emergency Department Transfers Due to Infection (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)

Probability that a resident is sent to the emergency department for an infection, overall for long stay and short stay resident subsets

Time frame: 18 months

Other Pre-specified

Hospital Transfers Due to Infection in Long Stay and Short Stay Subsets (Secondary Manuscript, Added by Steering Committee Decision on 3/22/2017)

Probability that a transfer to a hospital is due to an infection for long stay and short stay resident subsets

Time frame: 18 months

Other Pre-specified

Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)

Probability of colonization with any multidrug-resistant organism (MDRO): (MRSA, VRE, ESBL, CRE)

Time frame: Once in baseline and once at end-intervention (month 15-18 of intervention period)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
DecolonizationMultidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)176 Participants
Routine BathingMultidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)307 Participants

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026